Research ExplorerPublicationsEffects of oral niacin on endothelial dysfunction in patient...

Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study

Standard

Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study. / Warnholtz, Ascan; Wild, Philipp; Ostad, Mir Abolfazl; Elsner, Veronika; Stieber, Fabian; Schinzel, Reinhard; Walter, Ulrich; Peetz, Dirk; Lackner, Karl; Blankenberg, Stefan; Munzel, Thomas.

In: ATHEROSCLEROSIS, Vol. 204, No. 1, 05.2009, p. 216-221.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Warnholtz, A, Wild, P, Ostad, MA, Elsner, V, Stieber, F, Schinzel, R, Walter, U, Peetz, D, Lackner, K, Blankenberg, S & Munzel, T 2009, 'Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study', ATHEROSCLEROSIS, vol. 204, no. 1, pp. 216-221. https://doi.org/10.1016/j.atherosclerosis.2008.08.003

APA

Warnholtz, A., Wild, P., Ostad, M. A., Elsner, V., Stieber, F., Schinzel, R., Walter, U., Peetz, D., Lackner, K., Blankenberg, S., & Munzel, T. (2009). Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study. ATHEROSCLEROSIS, 204(1), 216-221. https://doi.org/10.1016/j.atherosclerosis.2008.08.003

Vancouver

Warnholtz A, Wild P, Ostad MA, Elsner V, Stieber F, Schinzel R et al. Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study. ATHEROSCLEROSIS. 2009 May;204(1):216-221. https://doi.org/10.1016/j.atherosclerosis.2008.08.003

Bibtex

@article{ceab696b736a4987814a452be8d40cff,
title = "Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study",
abstract = "High-density-lipoproteins-cholesterol (HDL-C) is invertedly related to the incidence of cardiovascular events. Recent studies suggest that HDL-C directly improves endothelial function. Nicotinic acid (niacin) effectively raises serum HDL-C. We therefore hypothesized that treatment with niacin improves endothelial dysfunction in patients with coronary artery disease (CAD). One hundred seven patients with CAD were randomly assigned to double-blinded treatment for 12 weeks with extended-release (ER)-niacin 1000 mg/day (N) or placebo (C), respectively. Flow-mediated dilation (FMD) of the brachial artery, nitroglycerin-mediated endothelium-independent dilation (NMD) and serum lipid concentrations were measured before and after treatment. Triglycerides (P=0.013), low-density-lipoprotein-cholesterol (LDL-C) (P=0.013) and HDL-C (P<0.0001) were altered by N compared to C. Niacin treatment was without effect on FMD or NMD, respectively, compared to placebo. However, post-hoc subgroup analysis revealed an improvement in FMD in patients with low HDL-C at baseline (absolute change in FMD (mean+/-S.D.) N: +3.25+/-3.88%, C: +1.03+/-2.71% in low tertile HDL-C ",
keywords = "Administration, Oral, Aged, Biomarkers/blood, Blood Glucose/drug effects, Brachial Artery/diagnostic imaging, Cell Adhesion Molecules/blood, Cholesterol, HDL/blood, Cholesterol, LDL/blood, Coronary Artery Disease/blood, Delayed-Action Preparations, Double-Blind Method, Endothelium, Vascular/drug effects, Female, Humans, Male, Microfilament Proteins/blood, Middle Aged, Niacin/administration & dosage, Nitroglycerin/administration & dosage, Phosphoproteins/blood, Phosphorylation, Prospective Studies, Treatment Outcome, Triglycerides/blood, Ultrasonography, Vasodilation/drug effects, Vasodilator Agents/administration & dosage",
author = "Ascan Warnholtz and Philipp Wild and Ostad, {Mir Abolfazl} and Veronika Elsner and Fabian Stieber and Reinhard Schinzel and Ulrich Walter and Dirk Peetz and Karl Lackner and Stefan Blankenberg and Thomas Munzel",
year = "2009",
month = may,
doi = "10.1016/j.atherosclerosis.2008.08.003",
language = "English",
volume = "204",
pages = "216--221",
journal = "ATHEROSCLEROSIS",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study

AU - Warnholtz, Ascan

AU - Wild, Philipp

AU - Ostad, Mir Abolfazl

AU - Elsner, Veronika

AU - Stieber, Fabian

AU - Schinzel, Reinhard

AU - Walter, Ulrich

AU - Peetz, Dirk

AU - Lackner, Karl

AU - Blankenberg, Stefan

AU - Munzel, Thomas

PY - 2009/5

Y1 - 2009/5

N2 - High-density-lipoproteins-cholesterol (HDL-C) is invertedly related to the incidence of cardiovascular events. Recent studies suggest that HDL-C directly improves endothelial function. Nicotinic acid (niacin) effectively raises serum HDL-C. We therefore hypothesized that treatment with niacin improves endothelial dysfunction in patients with coronary artery disease (CAD). One hundred seven patients with CAD were randomly assigned to double-blinded treatment for 12 weeks with extended-release (ER)-niacin 1000 mg/day (N) or placebo (C), respectively. Flow-mediated dilation (FMD) of the brachial artery, nitroglycerin-mediated endothelium-independent dilation (NMD) and serum lipid concentrations were measured before and after treatment. Triglycerides (P=0.013), low-density-lipoprotein-cholesterol (LDL-C) (P=0.013) and HDL-C (P<0.0001) were altered by N compared to C. Niacin treatment was without effect on FMD or NMD, respectively, compared to placebo. However, post-hoc subgroup analysis revealed an improvement in FMD in patients with low HDL-C at baseline (absolute change in FMD (mean+/-S.D.) N: +3.25+/-3.88%, C: +1.03+/-2.71% in low tertile HDL-C

AB - High-density-lipoproteins-cholesterol (HDL-C) is invertedly related to the incidence of cardiovascular events. Recent studies suggest that HDL-C directly improves endothelial function. Nicotinic acid (niacin) effectively raises serum HDL-C. We therefore hypothesized that treatment with niacin improves endothelial dysfunction in patients with coronary artery disease (CAD). One hundred seven patients with CAD were randomly assigned to double-blinded treatment for 12 weeks with extended-release (ER)-niacin 1000 mg/day (N) or placebo (C), respectively. Flow-mediated dilation (FMD) of the brachial artery, nitroglycerin-mediated endothelium-independent dilation (NMD) and serum lipid concentrations were measured before and after treatment. Triglycerides (P=0.013), low-density-lipoprotein-cholesterol (LDL-C) (P=0.013) and HDL-C (P<0.0001) were altered by N compared to C. Niacin treatment was without effect on FMD or NMD, respectively, compared to placebo. However, post-hoc subgroup analysis revealed an improvement in FMD in patients with low HDL-C at baseline (absolute change in FMD (mean+/-S.D.) N: +3.25+/-3.88%, C: +1.03+/-2.71% in low tertile HDL-C

KW - Administration, Oral

KW - Aged

KW - Biomarkers/blood

KW - Blood Glucose/drug effects

KW - Brachial Artery/diagnostic imaging

KW - Cell Adhesion Molecules/blood

KW - Cholesterol, HDL/blood

KW - Cholesterol, LDL/blood

KW - Coronary Artery Disease/blood

KW - Delayed-Action Preparations

KW - Double-Blind Method

KW - Endothelium, Vascular/drug effects

KW - Female

KW - Humans

KW - Male

KW - Microfilament Proteins/blood

KW - Middle Aged

KW - Niacin/administration & dosage

KW - Nitroglycerin/administration & dosage

KW - Phosphoproteins/blood

KW - Phosphorylation

KW - Prospective Studies

KW - Treatment Outcome

KW - Triglycerides/blood

KW - Ultrasonography

KW - Vasodilation/drug effects

KW - Vasodilator Agents/administration & dosage

U2 - 10.1016/j.atherosclerosis.2008.08.003

DO - 10.1016/j.atherosclerosis.2008.08.003

M3 - SCORING: Journal article

C2 - 18822413

VL - 204

SP - 216

EP - 221

JO - ATHEROSCLEROSIS

JF - ATHEROSCLEROSIS

SN - 0021-9150

IS - 1

ER -